Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

SABS

SAB Biotherapeutics Inc

Apr 29 • 04:00PM ET

4.19

Dollar change -0.06
Percentage change -1.41	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.11	Insider Own	18.89%	Shs Outstand	9.23M	Perf Week	-4.56%
Market Cap	38.67M	Forward P/E	-	EPS next Y	-6.21	Insider Trans	1.03%	Shs Float	7.48M	Perf Month	-7.71%
Income	-42.19M	PEG	-	EPS next Q	-0.96	Inst Own	37.69%	Short Float	0.34%	Perf Quarter	-30.05%
Sales	2.24M	P/S	17.27	EPS this Y	43.65%	Inst Trans	39.45%	Short Ratio	1.91	Perf Half Y	-55.89%
Book/sh	6.21	P/B	0.67	EPS next Y	-44.25%	ROA	-62.58%	Short Interest	0.03M	Perf Year	-53.44%
Cash/sh	6.13	P/C	0.68	EPS next 5Y	-	ROE	-95.51%	52W Range	4.00 - 11.90	Perf YTD	-39.05%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-68.77%	52W High	-64.79%	Beta	0.80
Dividend TTM	-	Quick Ratio	5.45	Sales past 5Y	-50.46%	Gross Margin	-67.28%	52W Low	4.75%	ATR (14)	0.28
Dividend Ex-Date	-	Current Ratio	5.45	EPS Y/Y TTM	-87.19%	Oper. Margin	-1700.56%	RSI (14)	41.86	Volatility	2.01% 4.59%
Employees	57	Debt/Eq	0.10	Sales Y/Y TTM	-90.63%	Profit Margin	-1884.50%	Recom	1.00	Target Price	15.50
Option/Short	No / Yes	LT Debt/Eq	0.07	EPS Q/Q	-2367.37%	Payout	-	Rel Volume	0.19	Prev Close	4.25
Sales Surprise	5179.17%	EPS Surprise	14.29%	Sales Q/Q	-85.88%	Earnings	Nov 14 BMO	Avg Volume	13.41K	Price	4.19
SMA20	-5.74%	SMA50	-12.35%	SMA200	-38.26%	Trades		Volume	2,681	Change	-1.41%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-05-21	Initiated	Chardan Capital Markets	Buy	$17

Apr-16-24 07:15AM	SAB Biotherapeutics Provides SAB-142 Trial Update (GlobeNewswire) +5.86%
Apr-08-24 07:15AM	SAB Biotherapeutics to Present at INNODIA Annual Meeting (GlobeNewswire)
Apr-04-24 07:15AM	SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-29-24 07:15AM	SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results (GlobeNewswire)
Mar-25-24 10:15AM	SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment (GlobeNewswire) -12.91%
08:00AM	Loading…
Feb-23-24 08:00AM	SAB Biotherapeutics to Present at the BIO CEO & Investor Conference (GlobeNewswire)
Feb-08-24 08:00AM	SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-02-24 07:30AM	SAB Biotherapeutics Announces Executive Leadership Change (GlobeNewswire)
Jan-23-24 05:58PM	SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jan-02-24 04:30PM	SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Nov-29-23 01:29PM	SAB Biotherapeutics Starts Human Clinical Trial of Diabetes Treatment (Exec Edge) -5.43%
07:30AM	SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes (GlobeNewswire)
Nov-20-23 07:30AM	SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors (GlobeNewswire)
Nov-14-23 01:35PM	SAB Biotherapeutics 3Q Loss Narrows, Completes $67.1M in Financing (Exec Edge)
07:30AM	SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes (GlobeNewswire)
07:15AM	Loading…
07:15AM	SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates (GlobeNewswire)
Nov-09-23 07:30AM	SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference (GlobeNewswire)
Oct-24-23 07:30AM	SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer (GlobeNewswire)
Oct-19-23 07:30AM	SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes (GlobeNewswire) +28.53%
Oct-05-23 07:30AM	SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors (GlobeNewswire)
Oct-03-23 11:31AM	SAB Biotherapeutics Will Sell $130 Million Shares of Preferred Stock to Advance Diabetes Treatment (Exec Edge)
Oct-02-23 07:30AM	SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes (GlobeNewswire)
Aug-21-23 08:30AM	SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results (GlobeNewswire)
Jul-12-23 11:04AM	Swiss Franc Jumps to Highest Against Dollar Since SNB Lifted Cap (Bloomberg)
Jun-21-23 08:30AM	SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023 (GlobeNewswire)
May-30-23 08:30AM	SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention (GlobeNewswire)
May-19-23 08:30AM	SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations (GlobeNewswire)
May-16-23 08:30AM	SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results (GlobeNewswire) -11.36%
May-12-23 08:30AM	SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies (GlobeNewswire)
May-09-23 08:30AM	SAB Biotherapeutics Announces Progress on U.S. FDAs Phased Review of Companys Groundbreaking DiversitAb Platform (GlobeNewswire) -6.22%
07:15AM	Loading…
07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-04-23 08:30AM	SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference (GlobeNewswire)
May-03-23 05:00PM	SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11 (GlobeNewswire)
Apr-26-23 08:30AM	SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications (GlobeNewswire) -6.90%
Apr-18-23 08:30AM	SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy (GlobeNewswire) +41.56%
Apr-13-23 08:30AM	SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza (GlobeNewswire) +99.71%
Apr-04-23 08:00AM	SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors (GlobeNewswire)
Mar-31-23 05:00PM	SAB Biotherapeutics Provides Company Update for Full Year 2022 (GlobeNewswire) +5.09%
Jan-19-23 08:00AM	SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference (GlobeNewswire)
Jan-18-23 08:30AM	SAB Biotherapeutics Gets Another $8.2 million from Department of Defense in Closeout Settlement (Exec Edge)
08:00AM	SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract (GlobeNewswire)
Jan-10-23 08:00AM	SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes (GlobeNewswire)
Jan-09-23 08:00AM	SAB Biotherapeutics CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase (GlobeNewswire) +11.46%
Jan-05-23 08:00AM	SAB Biotherapeutics Novel DiversitAb Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases (GlobeNewswire)
Dec-15-22 08:30AM	SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco (GlobeNewswire) -6.10%
Dec-11-22 08:20AM	Independent Director Jeffrey Spragens Just Bought 27% More Shares In SAB Biotherapeutics, Inc. (NASDAQ:SABS) (Simply Wall St.)
Dec-07-22 05:16PM	SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock (GlobeNewswire) -6.45%
Nov-21-22 08:14AM	SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes (GlobeNewswire) -9.17%
Nov-17-22 05:32AM	SAB Biotherapeutics Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-15-22 08:30AM	SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results (GlobeNewswire) -15.20%
Nov-08-22 08:30AM	SAB Biotherapeutics Presents Novel Biologic Therapeutics for Infectious Diseases at U.S. Pharma Partnering Summit 2022 (GlobeNewswire) +8.65%
Nov-03-22 09:00AM	SAB Biotherapeutics Presents Overview of DiversitAb Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference (GlobeNewswire)
Oct-27-22 08:30AM	SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions (GlobeNewswire) +6.33%
Sep-28-22 08:00AM	SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron (GlobeNewswire)
Sep-23-22 08:30AM	SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185s Effectiveness Against Multiple COVID-19 Variants (GlobeNewswire)
Aug-12-22 06:24AM	Need To Know: The Consensus Just Cut Its SAB Biotherapeutics, Inc. (NASDAQ:SABS) Estimates For 2022 (Simply Wall St.)
Aug-10-22 08:15AM	SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results (GlobeNewswire)
Aug-09-22 04:30PM	SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down (GlobeNewswire) -7.26%
Aug-04-22 08:30AM	SAB Biotherapeutics to Host Virtual 2022 Annual R&D Portfolio Update (GlobeNewswire)
Jul-11-22 08:00AM	SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors (GlobeNewswire) -8.94%
Jul-05-22 08:00AM	SAB Biotherapeutics Hosts U.S. Representatives Dusty Johnson and Dean Phillips for South Dakota Facility Tour (GlobeNewswire)
Jun-06-22 08:30AM	SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer (GlobeNewswire) -11.27%
May-31-22 08:30AM	SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit (GlobeNewswire)
May-12-22 04:15PM	SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results (GlobeNewswire)
09:42AM	SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-05-22 08:34AM	Shareholders in SAB Biotherapeutics (NASDAQ:SABS) are in the red if they invested a year ago (Simply Wall St.)
Apr-05-22 06:00AM	SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Companys Board of Scientific Advisors (GlobeNewswire) -13.80%
Mar-29-22 04:30PM	SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results (GlobeNewswire) +7.14%
Mar-02-22 06:00AM	SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations (GlobeNewswire) -39.87%
Mar-01-22 07:30PM	SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants (GlobeNewswire) -7.46%
Feb-25-22 06:00AM	SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19 (GlobeNewswire)
Feb-09-22 08:16AM	How Much Of SAB Biotherapeutics, Inc. (NASDAQ:SABS) Do Insiders Own? (Simply Wall St.)
Jan-24-22 06:00AM	SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19 (GlobeNewswire) +11.13%
Jan-19-22 05:38PM	First PREMIER Bank Buys SAB Biotherapeutics Inc, Amplify Transformational Data Sharing ETF, 3M ... (GuruFocus.com)
Jan-05-22 07:00AM	SAB Biotherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-20-21 06:00AM	SAB Biotherapeutics Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-16-21 06:00AM	SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro (GlobeNewswire) -6.36%
Dec-14-21 08:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SAB Biotherapeutics, Inc. - SABS (ACCESSWIRE)
Dec-01-21 07:00AM	SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus (GlobeNewswire)
Nov-30-21 07:52PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SAB Biotherapeutics, Inc. - SABS (GlobeNewswire) +6.56%
Nov-28-21 08:48PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SAB Biotherapeutics, Inc. - SABS (Newsfile)
Nov-25-21 11:27PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SAB Biotherapeutics, Inc. - SABS (PR Newswire)
Nov-22-21 05:41PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SAB Biotherapeutics, Inc. - SABS (GlobeNewswire) -10.24%
07:00AM	SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update (GlobeNewswire)
Nov-04-21 03:35PM	A Look At The Intrinsic Value Of SAB Biotherapeutics, Inc. (NASDAQ:SABS) (Simply Wall St.)
Oct-25-21 07:40AM	SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company (GlobeNewswire) -13.51%

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Sioux Falls, SD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sullivan Eddie Joe	Chief Executive Officer	Dec 07 '23	Buy	0.88	1,740	1,531	5,232,304	Dec 08 08:00 AM
King Michael	CHIEF FINANCIAL OFFICER	Nov 30 '23	Buy	0.90	5,000	4,500	5,000	Nov 30 05:00 PM
Reich Samuel J	Executive Chairman	Nov 29 '23	Buy	0.89	11,000	9,842	219,001	Nov 30 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SABS

SAB Biotherapeutics Inc

Upgrade your FINVIZ experience